Eptotermin alfa

Eptotermin alfa is a type of Bone Morphogenetic Protein (BMP) that is used in the treatment of bone fractures and spinal fusion surgeries. It is a recombinant human protein that promotes bone growth and healing.

History

Eptotermin alfa was developed by the biotechnology company Stryker Corporation. It was approved by the Food and Drug Administration (FDA) in the United States in 2002 for use in spinal fusion surgeries. It was later approved for use in the treatment of certain types of bone fractures.

Medical Uses

Eptotermin alfa is used in the treatment of orthopedic conditions such as spinal fusion surgeries and certain types of bone fractures. It is particularly useful in cases where the patient's own bone graft is not available or not desirable. Eptotermin alfa works by stimulating the body's own cells to produce bone.

Mechanism of Action

Eptotermin alfa is a type of Bone Morphogenetic Protein (BMP). BMPs are proteins that are naturally produced in the body and play a key role in the formation of bone and cartilage. Eptotermin alfa works by binding to specific receptors on the surface of cells, triggering a series of reactions that lead to the formation of bone.

Side Effects

Like all medications, eptotermin alfa can cause side effects. The most common side effects include pain at the injection site, infection, and abnormal bone growth. In rare cases, eptotermin alfa can cause serious side effects such as allergic reactions and problems with the nervous system.

See Also

• Bone Morphogenetic Protein
• Stryker Corporation
• Food and Drug Administration